TITLE

Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics

AUTHOR(S)
Rainer, M.; Mucke, H. A. M.; Krüger-Rainer, C.; Kraxberger, E.; Haushofer, M.; Jellinger, K. A.
PUB. DATE
November 2001
SOURCE
Journal of Neural Transmission;Nov2001, Vol. 108 Issue 11, p1327
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Summary. In a cross-sectional study of outpatients diagnosed with dementia of the Alzheimer type who had been treated with a broad variety of drugs supposed to improve cognition or to delay cognitive decline, we have investigated the effects of abruptly discontinuing therapy on cognition. Termination of therapy with any cholinesterase inhibitor was associated with a cognitive decline during the following 6–7 weeks which was significantly more pronounced than that experienced by patients who had received nootropic drugs or calcium channel blockers (3.41 vs. 1.17 points on the ADAS-Cog scale; -1.14 vs. -0.06 points on the MMSE scale). This effect was not modified by gender, apolipoprotein E genotype, or the extent of ventricular enlargement on CT scans. Its magnitude was comparable to the cognitive response observed in published clinical trials when cholinesterase therapy commenced, and also with the data obtained during a 6-week placebo washout phase.
ACCESSION #
15394910

 

Related Articles

  • Mild cognitive impairment.  // Practical Neurology;Apr2008, Vol. 46 Issue 4, p134 

    The article reports on the finding of a systematic review that the use of cholinesterase inhibitors in mild cognitive impairment was not associated with any delay in the onset of dementia or Alzheimer's disease. Three published and five unpublished trials met the inclusion criteria of the...

  • A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease. Tárraga, L.; Boada, M.; Modinos, G.; Espinosa, A.; Diego, S.; Morera, A.; Guitart, M.; Balcells, J.; Lopez, O. L.; Becker, J. T. // Journal of Neurology, Neurosurgery & Psychiatry;Oct2006, Vol. 77 Issue 10, p1116 

    Objective: To determine the usefulness of an interactive multimedia internet-based system (IMIS) for the cognitive stimulation of Alzheimer's disease. Methods: This is a 24-week, single-blind, randomised pilot study conducted on 46 mildly impaired patients suspected of having Alzheimer's disease...

  • Efficacy and Safety of Rivastigmine in the Treatment of Behavioural and Psychological Symptoms in Chinese Dementia Patients: an Open-Label Study. Chan, C. F.; Chan, W. C.; Li, S. W. // Hong Kong Journal of Psychiatry;2006, Vol. 16 Issue 3, p101 

    Objectives: Behavioural and psychological symptoms of dementia are integral features of Alzheimer's disease. They have been recognised as important predictors for premature institutionalisation and constitute major caregiver burdens. This study examined the efficacy of rivastigmine in the...

  • Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease. Connelly, P. J.; Prentice, N. P.; Fowler, K. G. // Journal of Neurology, Neurosurgery & Psychiatry;Mar2005, Vol. 76 Issue 3, p320 

    Objective: To investigate the possibility that response to cholinesterase inhibitor therapy could be predicted by easily measurable variables that are known to change as a result of treatment (such as the Mini Mental State Examination), measures of function (such as the instrumental activities...

  • Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer's disease. Standridge, John B. // Evidence Based Mental Health;Nov2004, Vol. 7 Issue 4, p112 

    The article presents an answer to the clinical question related to the effect of donepezil in people with mild to moderate Alzheimer's disease. The superiority, typically in cognition, of donepezil and other cholinesterase inhibitors (ChEls) to placebo has been confirmed in a systematic review....

  • Questionable recommendations for cholinesterase inhibitor use in AD.  // PharmacoEconomics & Outcomes News;8/27/2005, Issue 485, p5 

    Discusses research being done on the use of cholinesterase inhibitors for patients with Alzheimer's disease. Reference to a study by Hanna Kaduszkiewicz and colleagues, published in the August 2005 issue of the "British Medical Journal"; Methodology of the study.

  • Do patients at high risk of Alzheimer's disease benefit from early treatment? Holt, Jim; Stiltner, Lynetta; Wallace, Rick // Journal of Family Practice;Jun2009, Vol. 58 Issue 6, p320 

    The article reports on the study that evaluates the benefits of early treatment in patients with high risk of Alzheimer's disease. It recognizes that fair to good evidence supports a benefit from treatment of early-stage Alzheimer's disease. It suggests that routine screening for dementia in...

  • The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients. Werber, E. A.; Gandelman-Marton, R.; Klein, C.; Rabey, J. M. // Journal of Neural Transmission;Jun2003, Vol. 110 Issue 6, p659 

    Summary. Centrally acting cholinesterase inhibitors (ChEIs) improve cognitive functions in Alzheimer's disease (AD) and other forms of dementia. Evaluation of treatment efficacy is based mainly on subjective assessment methods such as standardized neuropsychological tests. Therefore, an...

  • Treatment for dementia. Newson, Louise // GP: General Practitioner;10/20/2006, p47 

    The article presents information on the treatment for dementia. Five percent of people over the age of 65 years, and 20 percent of those aged over 80 years are affected by dementia in Great Britain. Evidence from randomised controlled trials shows that cholinesterase inhibitors, donepezil,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics